Mersana Therapeutics, Inc.
MRSN
$28.59
$0.240.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.01M | 3.06M | 2.75M | 16.36M | 12.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.01M | 3.06M | 2.75M | 16.36M | 12.60M |
| Cost of Revenue | 12.18M | 16.22M | 18.34M | 22.29M | 14.80M |
| Gross Profit | -1.17M | -13.16M | -15.59M | -5.93M | -2.21M |
| SG&A Expenses | 6.30M | 7.42M | 8.93M | 8.89M | 9.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.49M | 23.63M | 27.27M | 31.17M | 24.67M |
| Operating Income | -7.48M | -20.58M | -24.51M | -14.81M | -12.07M |
| Income Before Tax | -7.55M | -24.30M | -24.12M | -14.12M | -11.08M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 418.00K |
| Earnings from Continuing Operations | -7.55M | -24.30M | -24.12M | -14.12M | -11.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.55M | -24.30M | -24.12M | -14.12M | -11.50M |
| EBIT | -7.48M | -20.58M | -24.51M | -14.81M | -12.07M |
| EBITDA | -7.39M | -20.29M | -24.20M | -14.41M | -11.67M |
| EPS Basic | -1.51 | -4.87 | -4.85 | -2.86 | -2.34 |
| Normalized Basic EPS | -0.92 | -2.55 | -3.03 | -1.79 | -1.41 |
| EPS Diluted | -1.51 | -4.87 | -4.85 | -2.86 | -2.34 |
| Normalized Diluted EPS | -0.92 | -2.55 | -3.03 | -1.79 | -1.41 |
| Average Basic Shares Outstanding | 4.99M | 4.99M | 4.98M | 4.94M | 4.91M |
| Average Diluted Shares Outstanding | 4.99M | 4.99M | 4.98M | 4.94M | 4.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |